These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Update on endocrine therapy for breast cancer. Buzdar AU; Hortobagyi G Clin Cancer Res; 1998 Mar; 4(3):527-34. PubMed ID: 9533518 [TBL] [Abstract][Full Text] [Related]
4. Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life. Harwood KV Clin J Oncol Nurs; 2004 Dec; 8(6):629-37. PubMed ID: 15637958 [TBL] [Abstract][Full Text] [Related]
6. The influence of endocrine treatments for breast cancer on health-related quality of life. Buijs C; de Vries EG; Mourits MJ; Willemse PH Cancer Treat Rev; 2008 Nov; 34(7):640-55. PubMed ID: 18514425 [TBL] [Abstract][Full Text] [Related]
7. Hormonal approaches to breast cancer treatment and prevention: an overview. Vogel CL Semin Oncol; 1996 Aug; 23(4 Suppl 9):2-9. PubMed ID: 8824459 [TBL] [Abstract][Full Text] [Related]
8. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer. Tan SH; Wolff AC Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122 [TBL] [Abstract][Full Text] [Related]
9. Medical management of fibroids. Sankaran S; Manyonda IT Best Pract Res Clin Obstet Gynaecol; 2008 Aug; 22(4):655-76. PubMed ID: 18468953 [TBL] [Abstract][Full Text] [Related]
10. [New developments in hormonal therapy for breast cancer]. Tominaga T Gan To Kagaku Ryoho; 1996 May; 23(6):678-83. PubMed ID: 8645017 [TBL] [Abstract][Full Text] [Related]
11. Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature. Rivera JA; Christopoulos S; Small D; Trifiro M J Clin Endocrinol Metab; 2004 Jul; 89(7):3183-8. PubMed ID: 15240591 [TBL] [Abstract][Full Text] [Related]
12. The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer. Lai CH; Huang HJ Curr Opin Obstet Gynecol; 2006 Feb; 18(1):29-34. PubMed ID: 16493257 [TBL] [Abstract][Full Text] [Related]
13. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women. Mouridsen HT Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085 [TBL] [Abstract][Full Text] [Related]
14. [New developments in the hormonal treatment of breast cancer in postmenopausal women]. Trunet P; Marty M Bull Cancer; 1999 Oct; 86(10):815-20. PubMed ID: 10572232 [TBL] [Abstract][Full Text] [Related]
15. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer. Baumann CK; Castiglione-Gertsch M Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839 [TBL] [Abstract][Full Text] [Related]
16. Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature. Schilder CM; Schagen SB Minerva Ginecol; 2007 Aug; 59(4):387-401. PubMed ID: 17923830 [TBL] [Abstract][Full Text] [Related]
17. Endocrine therapy of advanced disease: analysis and implications of the existing data. Pritchard KI Clin Cancer Res; 2003 Jan; 9(1 Pt 2):460S-7S. PubMed ID: 12538501 [TBL] [Abstract][Full Text] [Related]
18. Adherence to long-term adjuvant hormonal therapy for breast cancer. Gotay C; Dunn J Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-15. PubMed ID: 22098287 [TBL] [Abstract][Full Text] [Related]